OXFORD, England, February 22, 2011 /PRNewswire/ -- PharmaDeals(R) research has revealed that the early stages of recovery are now evident within pharmaceutical deal-making activity. The overall number of deals in 2010 grew relative to 2009, and whilst collaborative R&D deals continue to decline in numbers and value, licensing activity is on the increase.
Fintan Walton, PhD, Chief Executive of PharmaVentures, says, "The current deal-making landscape in the life science industry is fascinating, and reflects the forces for change operating worldwide. For example, research based on our PharmaDeals database shows that deal structures for M&A transactions are becoming more and more complex, yet values are declining. In order to benefit, small and large companies alike will require increasing levels of sophistication in terms of their deal-making ability." The results were recently presented by Dr Walton at the Sachs 4th Annual European Life Sciences CEO Forum for Partnering & Investing held in Zurich, and through analysis published by the journal PharmaDeals Review.
Anne Vindenes Allen, Executive Director for PharmaDeals, explains, "It is vital for industry deal makers to keep pace with these developments and use best available business intelligence. Analysis of our PharmaDeals data shows the variation in values within different deals types, as well as within development stages and therapy areas. We always go the extra mile to source and classify critical information to help our clients distil critical intelligence."
Fintan Walton concludes, "Our consultants help bring companies together to further their mutual aims - it's all about teasing out the win-win scenarios. Without an appreciation for what others are doing in the industry, that is pretty much an impossible task."
PharmaDeals v4 is the world's first online, multimedia, dedicated to the pharmaceutical and biotechnology industry, deals intelligence resource. Data for the report, 'Deal Making in 2010' - an annual review - was obtained from analysis of the PharmaDeals v4 Agreements database.
Secure a copy of the PharmaDeals Review article, entitled 'Deal Making in 2010' here http://www.pharmadeals.net/download_deal_making_2010
Journal available at http://www.pharmadealsreview.com
PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. PharmaVentures produces the highly popular PharmaDeals(R) (http://www.pharmadeals.net) range of intelligence products including analysis tools and reports. Its subsidiary, PharmaTelevision Limited, offers the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) (http://www.pharmatelevision.com).
Now in its 19th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.
PharmaDeals(R) and PharmaTelevision(R) are registered Trade Marks of PharmaVentures Ltd.
For further information: Anne Vindenes Allen Executive Director, PharmaDeals +44(0)1865-332700 email@example.com